Cabaletta Bio, Inc.
Cabaletta Bio is a clinical-stage biotechnology company focused on developing engineered T cell therapies for patients with autoimmune diseases. Its CABA platform uses the CARTA approach, or Chimeric Antigen Receptor T cells for Autoimmunity. Its lead product candidate, rese-cel, is a fully human CD19-CAR T therapy designed to deplete B cells after a single infusion. Cabaletta is evaluating rese-cel in clinical trials for systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis and pemphigus vulgaris, including cohorts without preconditioning. Cabaletta develops product candidates for potential use across autoimmune diseases with B cell involvement. Its manufacturing strategy relies on external suppliers, including contract and development manufacturing organizations, and it is working with Cellares on automated rese-cel manufacturing. The company was founded in 2017 to develop engineered cell therapies for autoimmune disease and is headquartered in Philadelphia, Pennsylvania.
No SEC Form 4 filings for $CABA in the last 30 days.
See all $CABA insider activity →Cabaletta Bio (CABA) presented Phase 1/2 data for its autoimmune therapy, resecabtagene autoleucel, at a conference. The therapy showed positive results in four autoimmune diseases, with high safety and efficacy. The company plans to submit a Biologics License Application in Q1 2028. CABA is recruiting for a registrational systemic sclerosis cohort.
Cabaletta Bio (CABA) reported durable responses in a small cohort of patients with dermatomyositis, lupus nephritis, and systemic sclerosis. 16 of 6 dermatomyositis patients responded at 1 year, 25 of 5 lupus nephritis patients achieved DORIS remission, and 35 of 7 systemic sclerosis patients achieved rCRISS-50. Additionally, 45 ILD patients showed a 9% mean FVC improvement at 1 year. The data, while promising, are based on small cohorts and require further confirmation.
Cabaletta Bio reported no revenue in Q3 2026, with a net loss of $53.05M, widening from $44.87M a year ago. R&D costs rose $7.3M, driven by higher manufacturing and clinical-trial expenses. The company is advancing clinical trials and expects to update plans in early 2027. According to the company, manufacturing partners include Lonza, ElevateBio, and Cellares.
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning CABA (Cabaletta Bio, Inc.). Coverage has been balanced: 2 bullish, 1 neutral, and 2 bearish.
Recent CABA coverage spans earnings, financial news and corporate actions.
Positive early‑stage data may lift the stock as investors reassess the therapy's commercial potential.
Positive early‑stage data may boost investor sentiment and drive short‑term price appreciation.
Earnings miss with widened loss likely pressures the stock lower.
The loss and cash burn may pressure the stock, while the cash runway to 2028 provides some runway.
Likely modest upside as cash runway extension and upcoming data reduce financing risk, but no immediate catalyst.
AlphAI scores every news story that mentions CABA with an AI model for sentiment and relevance, and aggregates insider trades from Cabaletta Bio, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Cabaletta Bio (CABA) presented Phase 1/2 data for its autoimmune therapy, resecabtagene autoleucel, at a conference. The therapy showed positive results in four autoimmune diseases, with high safety and efficacy. The company plans to submit a Biologics License Application in Q1 2028. CABA is recruiting for a registrational systemic sclerosis cohort.
Cabaletta Bio (CABA) reported durable responses in a small cohort of patients with dermatomyositis, lupus nephritis, and systemic sclerosis. 16 of 6 dermatomyositis patients responded at 1 year, 25 of 5 lupus nephritis patients achieved DORIS remission, and 35 of 7 systemic sclerosis patients achieved rCRISS-50. Additionally, 45 ILD patients showed a 9% mean FVC improvement at 1 year. The data, while promising, are based on small cohorts and require further confirmation.
Cabaletta Bio reported no revenue in Q3 2026, with a net loss of $53.05M, widening from $44.87M a year ago. R&D costs rose $7.3M, driven by higher manufacturing and clinical-trial expenses. The company is advancing clinical trials and expects to update plans in early 2027. According to the company, manufacturing partners include Lonza, ElevateBio, and Cellares.
Cabaletta Bio reported a Q3 2026 net loss of $53.1M, with cash of $299.4M expected to fund operations into Q1 2028. R&D expenses rose to $47.1M from $39.8M YoY. The company anticipates myositis topline results in H2 2027 and a BLA submission in Q1 2028, with ongoing clinical trials in lupus, myasthenia gravis, and pemphigus vulgaris.
Cabaletta Bio, Inc. (CABA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cabaletta Bio Reports Third Quarter 2026 Financial Results and Provides Business Update RESET-Myositis ® registrational adult topline results anticipated in 2H27 with BLA submission in 1Q28, including Phase 1/2 juvenile dermatomyositis data for potential PRV eligibil
Cabaletta Bio, Inc. (CABA) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. In connection with Cabaletta Bio’s (the “Corporation”) June 2025 underwritten public offering, the Corporation issued 53,090,190 common stock warrants (the “Common Stock Warrants”) that had an exercise price of $2.50 per whole share of its common stock and
Investing.com reports Cabaletta Bio (CABA) shares fell about 1.6% after Q2 2026 results. Net loss was $(0.73) per share, down 30% year over year. Cash was about $225.1M, expected to fund operations only into mid-2027. The update included Phase 1/2 data and a new CMC partner, plus an SEC Form 8-K.
Cabaletta Bio, Inc. (CABA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update Registrational RESET-Myositis ® clinical data on track to be reported in mid-2027 to support 2H27 BLA submission for rese-cel Juvenile myositis Phase 1/2 data expected to be subm
Cabaletta Bio, Inc. (CABA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K 0001759138 --12-31 false 0001759138 2026-06-09 2026-06-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): J
Cabaletta Bio (NASDAQ:CABA) reported positive early clinical and translational data from the first four patients in the lowest-dose cohort of preconditioning-free (PC-free) rese-cel, an investigational autologous CAR T therapy for autoimmune diseases, and manufacturing/translational results from the first two autoimmune patients treated using the Cellares Cell Shuttle platform. The company said higher doses may be needed without preconditioning and that 50% showed drug-free responses for six mon
